Michael Gilman

Michael Gilman is an accomplished leader in the biotechnology and pharmaceutical industries, currently serving as Chief Executive Officer at Arrakis Therapeutics since October 2016. Gilman has a strong track record of founding and leading innovative companies, including Padlock Therapeutics and Stromedix, both of which developed targeted therapies for specific diseases. Previous roles include Senior Vice President at Biogen Idec, where oversight of substantial clinical development programs was achieved, and Executive Vice President at Biogen, managing extensive research operations. Gilman's earlier experience includes significant positions at ARIAD Pharmaceuticals and Cold Spring Harbor Laboratory, with a robust educational foundation in biochemistry from the University of California, Berkeley, and life sciences from the Massachusetts Institute of Technology.